Peripheral thrombocytopenia

There is 1 paper on peripheral thrombocytopenia in aging research: 1 trial in people.

Disease

1 paper studies it1 finding

See all 1 papers on peripheral thrombocytopenia

  • Human trial1

Interventions

1

Navitoclax

upin humans1OR 4

1 study
  1. Navitoclax induces peripheral thrombocytopenia in humans (attributed to high-affinity BCL-XL inhibition) (grade 3 or 4 thrombocytopenia in 29 patients).

    “Navitoclax has a novel mechanism of peripheral thrombocytopenia and T-cell lymphopenia, attributable to high-affinity inhibition of BCL-XL and BCL-2, respectively.”

    Human trialattributed to high-affinity BCL-XL inhibition

    Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

    The Lancet. Oncology

More on Navitoclax

Latest